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Aim: to determine if local, in addition to systemic antibiotic prophylaxis (compared to that provided by systemic
prophylaxis alone) provides additional benefit in terms of reducing graft infection.
Methods: gelatin-sealed Dacron grafts were interposed in the infrarenal aorta of 36 mongrels and inoculated with 1 ml
of a S. aureus suspension. Group 1 (control group) received no prophylaxis and were inoculated with 1 ml containing
109 cfu/ml. Group 2 (n=6) received systemic prophylaxis (1 g cephamandole) and were inoculated with 105 cfu/ml (n=
3) or 107 cfu/ml (n=3). Group 3 received systemic prophylaxis (1 g cephamandole) and were inoculated with 109 cfu/ml.
Group 4 received systemic prophylaxis (2 g cephamandole) and were inoculated with 109 cfu/ml. In group 5 and 6 grafts
were soaked in a rifampicin solution before use and inoculated with 109 cfu/ml. Group 5 received no systemic prophylaxis
and group 6 received systemic prophylaxis (1 g cephamandole). Grafts were harvested at 2 weeks, and peritonitis, perigraft
abscess, anastomotic disruption and graft occlusion recorded. Swabs were taken of the graft, the perigraft tissues and the
peritoneal fluid. Graft segments were incubated in broth medium.
Results: inoculation with 109 cfu/ml ensured graft infection. Sytemic or local prophylaxis alone failed to prevent graft
infection. Only systemic and local antibiotic prophylaxis provided significant better results than no prophylaxis at all
(p<0.01) and local prophylaxis alone (p<0.05). However, total “graft sterility” was not achieved as bacteriologic analysis
of the graft segments showed low bacterial counts (<10 bacteria/graft) in 5 of 6 grafts.
Conclusion: local and systemic prophylaxis provided more protection as demonstrated by the significant decrease in the
incidence of “overt” graft infection. Total “graft sterility” cannot be expected in the case of an overwhelming bacterial
challenge.
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Introduction graft infections9 and amputations rates of up to 80% for
infrainguinal prosthetic graft infection.10 The etiology
The incidence of prosthetic vascular graft infection considered to be multifactorial and to be related to
the type of surgery and approach, the presence of(PVGI) is estimated at 0.5–6%.1–7 The consensus paper
by the Joint Councils of the Society for Vascular Surgery ulcers or gangrene and the graft material used. The
causative organisms are predominantly S. aureus andand International Society for Cardiovascular Surgery
quotes prosthesis location-dependent acceptable epidermidis,2–4,11 but infections can also be due to other
micro-organisms.12,13 Most commonly contaminationwound infection rates from maximal 1% for intra-
cavitary grafts to maximal 3% for grafts confined to occurs at the time of graft insertion and the most
frequent source of infection is from staphylococci froman extremity.8
The consequences of PVGI may be disastrous with the patient’s skin.2,3,14 Other potential sources are bac-
teria in the thrombus within an aneurysm or in thean associated mortality of 25% to 88% for aorto-iliac
arterial wall15 and haematogenous1/lymphatic3 spread
in association with ulcers and gangrene.
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PVGI.16–20 However, despite systemic prophylaxis, S. aureus was kept cryopreserved at −76 °C. On the
day of the operation an inoculum of bacteria wasPVGI still occurs. It is therefore justified to look for
ways to reduce the risk of PVGI. An option consists added to 0.9% isotonic saline to obtain the desired
concentration of bacteria which ranged from 105 toof bonding an antibiotic to the graft.21–23 Such antibiotic-
impregnated grafts have shown to be highly resistant 109 cfu/ml. One ml was used for topical inoculation
of the graft. The viability of the bacteria was tested byto bacterial contamination in animal models.24–28
The aim of this study was to assess if PVGI in placing a drop of the solution into a blood agar plate
(Mercoplatte, Merck, Darmstadt, Germany), enablingan animal model challenged with a high bacterial
concentration could be reduced further by the use of phage typing and antibiotic sensitivity testing. The
concentrations used were confirmed routinely by per-rifampin-impregnated gelatin-sealed Dacron grafts in
addition to systemic antibiotic prophylaxis. forming serial dilutions on the inocula and culturing
overnight.
Methods
Animal model
Graft material
This study was approved by the Animal Care and
Ethics Committee of the Regional Council of the Fed-Standard, commercially available gelatin-sealed knit-
ted polyester grafts (Uni-Graft DV, B. Braun Mel- eral State Hessen, Germany. All animals received ap-
propriate care in compliance with the “Guidelinessungen AG, Melsungen, Germany) were used in this
study. All grafts were 8 mm in diameter. For the an- for the Care and Use of Laboratory Animals of the
European Council” from 24 November 1986, Sup-imals in group 5 and 6 the graft material was soaked in
rifampicin (Rifa 600 mg, Gru¨nenthal GmbH, Stolberg, plement II – Article 5.
Adult mongrels were used as an experimental modelGermany) at a concentration of 600 mg in 10 ml isotonic
saline solution for 15 min at 38 °C before use, a con- (age: 1–2 years; weight: 25–35 kg). All surgical pro-
cedures were performed under general anaesthesia. Acentration which is also used in clinical practice.29
premedication of propionylpromazine (0.05 ml i.m./
kg) (Combelen, Bayer, Leverkusen, Germany) and
atropine sulphate (0.05 mg i.v./kg) (Atropinsulfat
Bacterial strain Braun 0.5 mg, B. Braun Melsungen AG, Melsungen,
Germany) was given 30 min prior to induction of
The S. aureus used in this experiment was obtained anaesthesia. Induction was performed with thiopental-
from the German Collection of Microorganisms and sodium (10 mg i.v./kg) (Trapanal, Byk Gulden, Kon-
Cell Cultures, Braunschweig (strain DSM 799 or Amer- stanz, Germany) and anaesthesia maintained with oxy-
ican Type Culture Collection – ATCC: 6538). This strain gen and thiopental. The animals received 1 g of
is sensitive to several antibiotics including ce- intravenous cephamandole (Mandokef, Lilly, Bad
phalosporins, gentamycin, and vancomycin, and is Homburg, Germany) in 10 ml of sterile isotonic saline
used as reference strain in testing the level of resistance administered before the induction of anaesthesia, ex-
to antibiotics. Sensitivity to rifampin was dem- cept group 1 and 5, the dogs in group 4 received 2 g
onstrated by in vitro testing. S. aureus was reactivated cephamandole. Blood (5 ml) for bacteriologic analysis
by incubation in 1 ml C.S.-Bouillon (CASO-Bouillon, was obtained before operation.
Merck, Darmstadt, Germany) in an aerobic atmosphere
at 35 °C for 2 h. The reactivated S. aureus were further
incubated in 100 ml C.S.-Bouillon in an aerobic at-
mosphere at 35 °C for 24 h. Inoculum preparation was Operative procedure
performed by cultivating 0.1 ml of this solution in
100 ml C.S.-Bouillon at 35 °C for 24 h (first 0.1% in- Through a median laparotomy, they underwent re-
placement of the infrarenal aorta with a gelatin-sealedoculation). In a second step, 0.1 ml of the first 0.1%
inoculation was incubated in 100 ml C.S.-Bouillon at Dacron graft under sterile surgical conditions. The
infrarenal aorta was exposed to the trifurcation and35 °C for 24 h (second 0.1% inoculation). The number
of viable organisms present after incubation was ex- all lumbar branches were ligated. The aorta was
clamped and excised after injecting 500 IU heparinpressed as the number of colony forming units (cfu)
per ml of broth. After 3 days of inoculum preparation, sodium (Heparin Sodium, B. Braun Melsungen AG,
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Table 1. Treatment groups. fluid. Graft segments of 50 mm were excised for quan-
titative bacteriologic analysis and incubated into aSystemic RIGS-graft Inoculum
cephalosporin (Uni-Graft DV) (cfu/ml) brain-heart infusion at 37 °C for at least 2 days. All
isolates from the grafts were phage typed to ensure
Group 1 n=6 – – 109 that the strain cultured corresponded to the inoculatedGroup 2a n=3 1 g – 105
Group 2b n=3 1 g – 107 strain. A positive bacteriologic analysis of a graft seg-
Group 3 n=6 1 g – 109 ment was defined as a graft infection.
Group 4 n=6 2×1 g – 109
Group 5 n=6 – 600 mg/10 ml 109
Group 6 n=6 1 g 600 mg/10 ml 109
RIGS-graft: Rifampicin-impregnated gelatin-sealed graft. Statistical analysis
The data from the study were analysed with the t-Melsungen, Germany) both proximally and distally to
test. Statistical significance was assigned when p valuesthe clamp beforehand. A 8–10 cm length graft was
were less than 0.05.implanted in an end-to-end fashion (Miralene, USP
5/0, B. Braun Melsungen AG, Melsungen, Germany).
After securing haemostasis and restoring blood cir-
culation, grafts were inoculated with 1 ml of isotonic
Resultssaline solution containing different concentrations of
S. aureus (Table 1). For the animals in group 5 and 6
All the dogs were successfully grafted. One animal inthe graft was soaked in rifampin at a concentration of
group 5 and one in group 1 died from sepsis on the600 mg in 10 ml isotonic saline solution for 15 min at
third and eleventh postoperative days, respectively.38 °C before implantation. Finally, the graft was
The other animals tolerated the procedure well andcovered by reapproximating the retroperitoneum and
survived to postoperative day 14, even in the presencethe abdomen was closed in layers with a standard
of an established PVGI. Abscess formation complicatedsurgical technique. After the operation the animals
wound healing in one animal in group 1, and woundwere kept singly and had free access to food and
healing was delayed in six animals without evidencewater. No infusion therapy was given. General state
of wound infection. No abnormalities were observedof health (body temperature, appetite, behaviour) and
in the other animals. Behaviour, appetite, and generalwound healing were monitored daily. Blood samples
state of health were not impaired in the surviving(5 ml) for bacterial counts were obtained pre-
animals, although the occasional dog had an elevatedoperatively, 24 h postoperatively, and at 2-day intervals
temperature on postoperative day 14. The macroscopicthrough the end of the study. Serum and urine samples
findings such as abdominal adhesions, degree of peri-were obtained 24 h after operation for antibiotic
tonitis, abscess formation, and perigraft inflammationassays.
and exudate between the different groups are outlined
in Table 2.
Harvest and graft analysis
At the end of the study period of 2 weeks, the surviving Autopsy findings
animals (n=34) were reanaesthetised. Before operation
blood samples were obtained for bacteriologic analysis. At the time of retrieval, all implanted grafts were
patent. No infected pseudoaneurysm was found. AllThe aortic graft was exposed through the previous
median laparotomy under sterile surgical conditions. grafts of group 1 and 4 revealed manifest signs of
local infection (Table 2). The grafts were not in-The grafts were evaluated for graft patency, and signs
of local infection were noted, including abscess for- corporated and surrounded by a cavity filled with a
suppurative exudate and the perigraft tissue revealedmation, inflammation of perigraft tissue, presence of
perigraft exudates, degree of graft incorporation, peri- signs of acute inflammation. Two grafts of group 3
were macroscopically intact and two grafts presentedtonitis, and dehiscence or false aneurysm formation
at the sites of the anastomoses. The implanted grafts a mural thrombus. All animals of group 5 had evidence
of PVGI. Four animals of group 6 were healthy at thewere completely excised, including 15 mm of the aorta
proximal and distal to the anastomoses. Cultures were time of death, in two animals the graft was surrounded
by a suppurative haemorrhagic exudate.taken of the graft, the perigraft tissues and perigraft
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Table 2. Autopsy findings.
Peritoneum Abdominal Omentum Peritoneal exudate Perigraft exudate
adhesions (ml) (ml)
Group 1 +++ ++ ++ – <5 (P)
++ – ++ – <5 (H-P)
++ – +++ 50 (H) <5 (H-P)
+++ – +++ – 15 (H-P)
+++ – +++ 50 (H-P) <5 (H-P)
+++ ++ +++ – <5 (H)
Group 3 ++ +++ +++ <5 <5 (H-P)
++ ++ +++ <5 (P) 15–20 (H-P)
+ +++ ++(+) <10 <5
++ ++ (+) – <5
+++ +++ ++(+) <10 (P) 30 (P)
normal ++ + – <5 (H)
Group 4 +++ +++ +++ 600 (H-P) 50 (P)
normal + +(+) <5 <5
normal ++ normal – 50 (H-P)
(+) ++ (+) <5 15–20 (H-P)
+++ ++ + <5 <10
++ + normal – <5
Group 5 – – – – <5 (H-P)
– + – – 5 (P)
+++ + +++ 500 (H) 75 (H-P)
++ – ++ – 20–30 (P)
+++ +++ ++ – <5 (H)
++ – ++ <5 (H) 20 (P)
Group 6 normal – (+) – <5 (P)
normal + normal – <5
normal + normal – <5
++(+) + ++(+) <5 (H) 15 (H)
normal + normal – <5
normal – normal 5 (H) 20 (H-P)
Peritoneum: –: normal; +: moderate local peritonitis; ++: moderate diffuse peritonitis; +++: severe peritonitis. Abdominal adhesions:
+: isolated; ++: multiple small adhesions; +++: extensive. Omentum: –: normal; +: partial inflammation; ++: moderate inflamed
omentum; +++: severe inflamed omentum. Exudate: H: haemorrhagic; P: purulent.
Bacteriologic studies grafts.There was a good correlation between the bac-
terial counts of the perigraft fluid and the graft swab
All animals had sterile perioperative and postoperative findings (Table 3).
blood cultures. Twenty-four hours after graft im-
plantation, there were no detectable cephamandole or
rifampin concentrations in serum and urine.
Graft swab, graft material, and perigraft fluid Discussion
samples of groups 2a and 2b were sterile. Higher
bacterial concentrations were therefore used for graft There is now considerable evidence to show that sys-
temic antibiotic prophylaxis reduces the incidence ofcontamination in all other groups. Inoculation with
109 cfu/ml S. aureus produced PVGI in all animals of PVGI.16–20 The commonest form of antibiotic pro-
phylaxis used in vascular surgery is a systemic, broadgroup 1 and 4, and in four of the animals in group 3.
Rifampin-impregnated, gelatin-sealed Dacron grafts spectrum third generation cephalosporin. However,
prophylaxis alone cannot prevent PVGI, as also dem-alone (group 5) failed to prevent PVGI. Only systemic
and local antibiotic prophylaxis provided significant onstrated in experimental studies,23,30,31 alternative con-
cepts to reduce this risk are of major clinical interest.better results than no prophylaxis at all (p<0.01) and
local prophylaxis alone (p<0.05). The graft swabs of Antibiotic-impregnated grafts are an attractive op-
tion for prevention of PVGI as it potentially can deliver5/6 animals of group 6 were sterile. The grafts of
group 6 showed definitely low bacterial counts. How- antibiotic at the time that the graft is at greatest risk
of contamination. Several experimental studies haveever, total “graft sterility” was not achieved as bac-
teriologic analysis of the graft segments showed very demonstrated that antibiotic-impregnated grafts are
resistant to topical and intravenous challenge withlow bacterial counts (<10 bacteria/graft) in 5 of 6
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Table 3. Bacteriologic findings.
Graft swab Perigraft exudate Graft material
Group 1 n=6 + overgrowth 4×103
++ overgrowth 4×103
+++ 4.6×102 2.2×105
3.0×102 6.4×105 1.1×107
3.0×103 2.1×106 7.1×107
2.5×101 6.0×102 2.7×103
Group 2a n=3 sterile sterile sterile
sterile – sterile
sterile sterile sterile
Group 2b n=3 sterile – sterile
sterile sterile sterile
sterile sterile sterile
Group 3 n=6 200 103 104
100 103 104
100 102 104
sterile sterile sterile
sterile 2 101
sterile 30 sterile
Group 4 n=6 overgrowth overgrowth 104
sterile overgrowth <10
4 sterile <10
100 overgrowth 6×102
overgrowth overgrowth 103
15 60 7×101
Group 5 n=6 + overgrowth 4×104
+++ overgrowth 5.2×104
+++ overgrowth 3.4×107
overgrowth overgrowth 5.8×103
6 35 7.1×101
8 0 3.7×101
Group 6 n=6 2 3 101
sterile sterile <10
sterile sterile <10
sterile <10 <10
sterile sterile sterile
sterile sterile 1
bacteria.22–29,32–37 Rifampicin is appropriate as it is the graft infections.2 Inoculation with 105 or 107 cfu/ml
failed to produce PVGI in our study. Inoculation withmost effective antibiotic against coagulase positive and
negative staphylococci, and highly effective against 109 cfu/ml led to a manifest graft infection, indicating
that the load of organisms inoculated is an importantGram-negative micro-organisms.38 Despite well-
known side effects of systemic rifampicin therapy, factor in determining the development of a PVGI.
However, it cannot be determined whether lower bac-evidence of toxicity in animal or clinical studies has
not been reported. The impregnation of gelatin-sealed terial concentrations may produce graft infection in
man. Experimental data indicate that rifampin remainsgrafts with rifampicin relies on an ionic bonding be-
tween the negatively charged free carboxyl groups in active on the graft surface for only several days, graft
harvesting at 2 weeks was appropriate to test ourthe gelatin and the positively charged molecules of
rifampicin. Soaking of the grafts in a rifampicin so- hypothesis. A study of the long-term efficacy of local
and systemic prophylaxis in preventing PVGI islution at concentrations of 1 mg/ml up to 60 mg/ml
for 10–15 min at 38 °C has been shown to be effective planned. A striking finding in all groups was that the
three types of bacteriologic samples, i.e. graft swab,against topical and intravenous inoculation of S.
aureus, without development of rifampicin resist- perigraft fluid, and graft material, showed quasi ident-
ical results. Analysis of these three different types ofance.24,25,30,39–41
The question remains if local antibiotic prophylaxis bacteriologic samples was thus useful for confirmation
of findings rather than for achieving additional in-in addition to systemic prophylaxis could provide
additional benefit in reducing the risk of PVGI to that formation. The use of rifampicin-impregnated grafts
was not effective in preventing PVGI, as is evidencedprovided by systemic prophylaxis alone?
The study strain was an isolate of S. aureus, which by both the bacteriologic studies and the macroscopic
findings obtained at the time of graft explantation. Theis known to account for 35% to 50% of the vascular
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observation that antbiotic-impregnated grafts alone Rifampicin Bonded Graft European Trial (RBGET).
Both studies are not able to show a statistically sig-cannot prevent PVGI is consistent with the results
nificant benefit from the use of rifampin-impregnatedreported by other groups.26,42 Only the use of rifampin-
grafts for the prevention of PVGI, although there wasimpregnated, gelatin-sealed Dacron grafts in addition
a positive trend in favour of the treatment group.to systemic antibiotic prophylaxis provided better pro-
However, the RBGET study has shown to reducetection against PVGI than that provided by local or
significantly the incidence of wound infections, a pre-systemic prophylaxis alone. However, quantitative
disposing factor in the pathophysiology of PVGI. Bothbacteriologic analysis demonstrated very low bacterial
studies demonstrated similar differences (±0.3% tocounts in the graft segments of 5 of 6 animals. Similar
0.5%) in PVGI between the treatment group (ri-findings were reported by other groups.39 Hence, under
fampicin-impregnated grafts) and the control group.the experimental conditions of massive graft con-
In conclusion: (1) antibiotic-impregnated graftstamination used in this study, the combination of a
alone are not more effective than systemic antibioticsingle systemic antibiotic prophylaxis and use of an
prophylaxis alone at preventing the establishment ofantibiotic-impregnated graft failed to achieve total
a PVGI; (2) the use of rifampin-impregnated gelatin-“graft sterility”. An observation of 6 weeks or more
sealed Dacron grafts effectively decrease the incidenceseems necessary to evaluate eventual further bacterial
of overt manifestations of PVGI after topical in-growth. It can also not be determined whether sup-
oculation of an overwhelming bacterial challenge; (3)plemental systemic antibiotic therapy continued for
we recommend graft impregnation in a rifampin so-several days postoperatively would have completely
lution at a concentration of 600 mg/10 ml isotoniceliminated residual contaminations. Our study had
saline solution to achieve maximal graft resistancenot set out to look into this question and these con-
against a high bacterial concentration; (4) the combinedsiderations does not diminish the expressiveness of
use of systemic antibiotic prophylaxis and rifampin-our conclusion that the combined use of local and
impregnated Dacron grafts seems especially indicatedsystemic antibiotic prophylaxis seems to be more
in patients at greater risk for infection, such as surgeryeffective in preventing “overt” manifestations of PVGI
in potential infected areas and redo-surgery.than either modality alone. Our data suggest that the
clinical role of local antibiotic prophylaxis is as an
adjunct to the use of systemic antibiotic prophylaxis,
e.g. in clinical situations characterised by a high risk Acknowledgements
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